Merck Launches Industry-First Bio-Based Solvent Portfolio for (HPLC)

Date:

Share post:

In a significant step toward greener laboratory practices, Merck Group has launched the industry’s first bio-based solvent portfolio designed specifically for high-performance liquid chromatography (HPLC).Developed using renewable feedstocks, the patent-pending range offers a sustainable alternative to conventional fossil-based solvents without compromising analytical performance—an essential requirement in regulated environments such as pharmaceutical quality control and diagnostics.

The portfolio features drop-in replacements for commonly used HPLC solvents, including acetonitrile, methanol, and ethanol. These bio-based variants deliver an average reduction of 25.9% in CO₂ emissions compared to traditional HPLC-grade solvents, supporting the life sciences sector’s push toward lower environmental impact.

HPLC plays a critical role in the separation and quantification of compounds, where solvent purity and consistency directly influence data accuracy. Merck stated that its proprietary manufacturing processes ensure these bio-based solvents meet the same stringent quality and performance standards as conventional options, enabling seamless integration into existing workflows.

The launch expands Merck’s “Greener Alternative Products” portfolio and reflects a broader industry shift toward sustainable innovation. By offering environmentally responsible solutions without requiring changes to established analytical methods, the company aims to help laboratories align with global sustainability goals while maintaining scientific rigor.

By Pragna Biswas

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Bhawanipur Global Campus Announces iNATCONPH 2026: A Global Platform for Pharmacy & Allied Health Research

Kolkata: Bhawanipur Global Campus has announced the 16th International Conference - iNATCONPH 2026, a prestigious international scientific conference...

Emcure Pharma Receives CDSCO Approval to Launch Poviztra®️ for Fatty Liver Disease Treatment

Emcure Pharmaceuticals Ltd  announced that its co-marketed semaglutide brand, Poviztra®, has received regulatory approval from the Central Drugs...

CDSCO Partners with THSTI to Strengthen Vaccine and Healthcare innovation

The Central Drugs Standard Control Organization (CDSCO), India’s national regulatory authority, and the Translational Health Science and Technology...

EMeRG Launches Hospital Intel Suite™️ to transform MedTech Market

EMeRG, a leading healthcare intelligence provider with over a decade of industry expertise,  announced the launch of Hospital...